Weed (BUDZ) Long-Term Deferred Tax (2019 - 2026)

Weed (BUDZ) posted quarterly Long-Term Deferred Tax of $4.2 million for Q1 2026, up 5.27% quarter-over-quarter from $4.0 million in Q2 2025.

Weed (BUDZ) Long-Term Deferred Tax (2019 - 2026) Analysis & Trends

Weed's Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $4.2 million for Q1 2026.

In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (changed N/A YoY), while the FY2022 annual figure was $3.8 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q1 2026 stood at $4.2 million, up from $4.0 million in the prior quarter.
The five-year high for Long-Term Deferred Tax was $4.2 million in Q1 2026, with the low at $2.7 million in Q3 2022.
The 4-year median for Long-Term Deferred Tax is $3.8 million (2022), against an average of $3.7 million.
Peak annual rise in Long-Term Deferred Tax reached 35.39% in 2023, while the deepest fall reached 35.39% in 2023.
Weed's Long-Term Deferred Tax stood at $3.8 million in 2022, then declined by 2.04% to $3.7 million in 2023, then grew by 8.3% to $4.0 million in 2025, then advanced by 5.27% to $4.2 million in 2026.
Business Quant data shows BUDZ's Long-Term Deferred Tax at $4.2 million in Q1 2026, $4.0 million in Q2 2025, and $3.7 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.78 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.71 Bn	22.91 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.59 Bn	683.80 Mn
6	Viatris	18.72 Bn	17.83 Bn	1.46 Bn
7	Neurocrine Biosciences	15.57 Bn	15.18 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.97 Bn	-
10	Weed	2.88 Mn	2.88 Mn	-

Download Data